Multivalent meningococcal polysaccharide-protein conjugate vaccine

Patent metadata

Field	Value
Publication number	US-10143757-B2
Application number	US-201715816211-A
Country	US
Kind code	B2
Filing date	Nov 17, 2017
Priority date	Jan 23, 2001
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis . The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.

First claim

I claim:

1. A method of manufacturing an immunological composition capable of eliciting in children less than two years of age, a primary serum IgG response and a serum bactericidal antibody response to each of Neisseria meningitidis serogroups A, C, W-135 and Y capsular polysaccharides, the method comprising the steps of:
(a) purifying capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y;
(b) partially depolymerizing the purified capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y in a separate reaction;
(c) conjugating each of the purified, partially depolymerized capsular polysaccharides of step (b) to a purified single carrier protein species in a separate reaction, wherein four distinct and separately made carrier protein-capsular polysaccharide conjugates are made;
(d) mixing the four distinct and separately made carrier protein-capsular polysaccharide conjugates of step (c); and
(e) purifying the admixture of the four distinct and separately made carrier protein-capsular polysaccharide conjugates,

wherein the single carrier protein is selected from the group consisting of diphtheria toxoid, CRM 197 and tetanus toxoid, and further wherein, the serum bactericidal antibody response in children less than two years of age is higher than that elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine.

2. The method of claim 1 , wherein the immunological composition further comprises an adjuvant.

3. The method of claim 2 , wherein the adjuvant is an aluminum adjuvant.

4. The method of claim 3 , wherein the aluminum adjuvant is aluminum hydroxide.

5. The method of claim 3 , wherein the aluminum adjuvant is aluminum phosphate.

6. The method of claim 1 , wherein the carrier protein is diphtheria toxoid.

7. The method of claim 1 , wherein the carrier protein is CRM 197 .

8. The method of claim 1 , wherein the carrier protein is tetanus toxoid.

9. A method of manufacturing a conjugate vaccine capable of eliciting in children less than two years of age, a primary serum IgG response and a serum bactericidal antibody response to each of Neisseria meningitidis serogroups A, C, W-135 and Y capsular polysaccharides, the method comprising the steps of:
(a) purifying capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y;
(b) partially depolymerizing the purified capsular polysaccharides from each of the N. meningitidis serogroups A, C, W-135 and Y in a separate reaction;
(c) conjugating each of the purified, partially depolymerized capsular polysaccharides of step (b) to a purified single carrier protein species in a separate reaction, wherein four distinct and separately made carrier protein-capsular polysaccharide conjugates are made;
(d) mixing the four distinct and separately made carrier protein-capsular polysaccharide conjugates of step (c); and
(e) purifying the admixture of the four distinct and separately made carrier protein-capsular polysaccharide conjugates,

wherein the single carrier protein is selected from the group consisting of diphtheria toxoid, CRM 197 and tetanus toxoid, and further wherein, the serum bactericidal antibody response in children less than two years of age is higher than that elicited by the licensed, unconjugated, tetravalent A, C, W-135 and Y meningococcal capsular polysaccharide vaccine.

10. The method of claim 9 , wherein the conjugate vaccine further comprises an adjuvant.

11. The method of claim 10 , wherein the adjuvant is an aluminum adjuvant.

12. The method of claim 11 , wherein the aluminum adjuvant is aluminum hydroxide.

13. The method of claim 11 , wherein the aluminum adjuvant is aluminum phosphate.

14. The method of claim 9 , wherein the carrier protein is diphtheria toxoid.

15. The method of claim 9 , wherein the carrier protein is CRM 197 .

16. The method of claim 9 , wherein the carrier protein is tetanus toxoid.

Assignees

• Sanofi Pasteur Inc

Inventors

• Ryall Robert P

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K47/24

  containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

• A61K47/6415 Primary

  Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title